Retrospective assessment of everolimus treatment in patients suffering from advanced renal cell carcinoma
Journal Title: OncoReview - Year 2017, Vol 7, Issue 2
Abstract
Objective: Results of second-line everolimus treatment in clear cell renal carcinoma. Material and methods: Clinical data of 32 patients of the Clinic of Systemic and Metastatic Malignancies, Centre of Oncology, Maria Sklodowska-Curie Memorial Institute (Krakow Branch) treated with second-line everolimus between 2011 and 2016 were analysed. Results: Median progression-free survival was 7 months. Stable disease was observed in 24 cases. Adverse events occurred in 59% of all patients, and the majority were mild and moderate (G1 and G2) according to CTCAE. The most frequent adverse events included anaemia, stomatitis, rash and fatigue. Conclusion: Molecularly targeted drugs offer the only effective and available therapy in Poland, which can be administered in patients with advanced renal cell carcinoma. Second-line everolimus is a valuable therapeutic option in the above mentioned group (following progression on first-line TKI therapy), especially when it is necessary to avoid the accumulation of similar adverse events after TKI treatment (different toxicity profiles).
Authors and Affiliations
Paweł Hernik, Maksymilian Kruczała, Marek Ziobro
Keywords
Related Articles
- EP ID EP189866
- DOI 10.24292/01.OR.300617.6
- Views 201
- Downloads 0
Leczenie okołooperacyjne gruczolakoraka przełyku, połączenia przełykowo-żołądkowego oraz żołądka; nowe standardy postępowania i kontrowersje
Rak przełyku, połączenia przełykowo-żołądkowego oraz żołądka to duży problem diagnostyczny i terapeutyczny. Nawet po zabiegach chirurgicznych (R0) odsetek przeżyć 5-letnich jest niezadowalający. Chemioterapia okołooperac...
Therapeutic rehabilitation of cancer patients. Why and what for?
Types of oncological rehabilitation and its objectives are described. It includes information on many manifestations of oncological diseases that an internist has to deal with, which are conditioned not only by the oncol...
Off-label drug use in breast cancer therapy
Breast cancer is one of the most common malignancies across the world, including Poland. Chemotherapy plays an important part in the treatment of the disease. Most of the available chemotherapy drugs and regimens have un...
Czy antagoniści receptorów angiotensynowych AT1 (sartany) mogą zwiększać ryzyko wystąpienia choroby nowotworowej? Komentarz kardiologa i hipertensjologa
Long-term survivor of advanced synovial sarcoma - case report and literature review
Progress in metastatic renal cell carcinoma treatment is generally based on new registered drugs. This brings improvement of results but it also needs the choice of proper drug. The decision is especially important in in...